Pancreatic Adenocarcinoma

A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic gastrointestinal cancers than prior strategies, according to results of a phase 2 trial.

Patients with advanced cancer should be enrolled in early phase clinical trials during favorable points in their disease rather than after exhausting standard-of-care treatments, according to a paper published in JCO Oncology Practice.

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney cancer, according to results of a phase 1 trial.

Zenocutuzumab exhibited efficacy among patients with NRG1 fusion-positive cancers, according to phase 2 data published in The New England Journal of Medicine.

The FDA approved two oncology therapies for treatment of certain patients with lung cancer or pancreatic cancer.

PHILADELPHIA — An AI model achieved high accuracy in detecting and distinguishing between cystic and solid pancreatic focal lesions during endoscopic ultrasound procedures, according to data presented at the ACG Annual Scientific Meeting.

A consortium recommended classifying people with a high risk for pancreatic cancer into subtypes based on family history and germline variants, according to findings published in Journal of the National Comprehensive Cancer Network.

A study of eryaspase added to chemotherapy did not meet its primary endpoint of improved OS among patients with advanced pancreatic cancer, according to a presentation at ASCO Gastrointestinal Cancers Symposium.

The FDA granted orphan drug designation to MT-601, an investigational T-cell immunotherapy, for treatment of advanced or metastatic pancreatic adenocarcinoma.

The FDA cleared an investigational new drug application for CT041, a chimeric antigen receptor T-cell therapy for the treatment of adenocarcinoma of the stomach, gastroesophageal junction or pancreas.